FibrosisNCT06749522
Radiological Spectrum Of Fatty Liver Correlate With High Resolution Ultrasonography Of Fibrosis And Cirrhosis
An observational study of Fibrosis and Cirrhosis, run by Superior University at 1 site in Pakistan.
Trial summary
Fatty liver is a condition in which fat builds up in liver. it is very common health issue.it is major public health problems in the world. there is particular concern because fatty liver causes mortality among patients. The incidence and prevalence of disease vary with time. Read more about this study
- Who is it for?
- Ages 18 to 70 yearsHealthy volunteers can take part
- What is being tested?
- high resolution ultrasonography
- Type of treatment
- Surgery or procedure
- How many people
- 150 participants
- Where
- 1 sitePakistan
- Study dates
- 28 Feb 2024to 1 Mar 2025
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 70 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: to compare the Radiological Spectrum Of Fatty Liver Correlate With High Resolution Ultrasonography (CT, MRI) Of Fibrosis And Cirrhosis
Who may be able to join
- Confirmed diagnosis of fatty liver (steatosis), fibrosis, or cirrhosis.
- Patient consent to undergo imaging and participate in the study.
Who cannot join
- Other Liver Diseases: Exclusion of patients with other significant liver conditions (e.g., viral hepatitis, autoimmune liver diseases) unless specified.
- Pregnant women may be excluded due to imaging concerns.
- Poor quality or incomplete imaging studies.
- Presence of other severe systemic illnesses that could affect liver function or imaging.
- Recent liver surgeries or invasive procedures that might affect imaging results
Trial locations and contacts
1 site in 1 country.
About this study
Fatty liver is a condition in which fat builds up in liver. it is very common health issue.it is major public health problems in the world. there is particular concern because fatty liver causes mortality among patients. The incidence and prevalence of disease vary with time. Fibrosis is thickening of connective tissues which is usually as a result of injury and long term inflammation. Cirrhosis is severe scarring of liver which is caused by long term liver damage. The scar tissue replaces healthy tissues which leads to loss of liver function. The Objective of study is to look into radiographic features of fatty liver disease. The high resolution ultrasonography will give more detailed view of disease. The study inclued 150 participants.
Read the detailed description
The other liver conditions like fibrosis and cirrhosis are also examined and correlated with fatty liver disease. The CT and MRI are used to compare with HR ultrasonographic findings. Descriptive statistics and comparative statistics are used to interpret data.
- Being tested
- high resolution ultrasonography
- Medical subject headings
- Fibrosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
high resolution ultrasonographyRadiation
to compare high resolution ultrasonography finings with other imaging modalities(CT and MRI)
What is being measured
The primary outcome is the main question the study is designed to answer.
CT
CT used for the image comparision
Measured: 12 Months
MRI
CT used for the image comparision
Measured: 12 Months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Dec 2024
- Study start28 Feb 2024
- Primary completion1 Jul 2024
- Study completion1 Mar 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for FibrosisStudies of the same condition, open and under way.
- More trials run by Superior UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 150 participants (actual)
Sponsor and investigators
- Lead sponsor
- Superior University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Muhammad Naveed Babur, Superior University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06749522
- Sponsor's protocol ID
- MSAHS/Batch-Spring23/038
- Status last verified
- Dec 2024
- First submitted
- 19 Dec 2024
- Last updated
- 27 Dec 2024
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 27 Dec 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Radiological Spectrum Of Fatty Liver Correlate With High Resolution Ultrasonography Of Fibrosis And Cirrhosis
- ClinicalTrials.gov ID
- NCT06749522
- Acronym / sponsor ID
- MSAHS/Batch-Spring23/038
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 150 participants (actual)
- Lead sponsor
- Superior UniversityUniversity, hospital or other
- Study start
- 28 Feb 2024 (actual)
- Primary completion
- 1 Jul 2024 (actual)
- Study completion
- 1 Mar 2025 (estimated)
- First posted
- 27 Dec 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Fatty liver is a condition in which fat builds up in liver. it is very common health issue.it is major public health problems in the world. there is particular concern because fatty liver causes mortality among patients. The incidence and prevalence of disease vary with time. Fibrosis is thickening of connective tissues which is usually as a result of injury and long term inflammation. Cirrhosis is severe scarring of liver which is caused by long term liver damage. The scar tissue replaces healthy tissues which leads to loss of liver function. The Objective of study is to look into radiographic features of fatty liver disease. The high resolution ultrasonography will give more detailed view of disease. The study inclued 150 participants.
Detailed description
The other liver conditions like fibrosis and cirrhosis are also examined and correlated with fatty liver disease. The CT and MRI are used to compare with HR ultrasonographic findings. Descriptive statistics and comparative statistics are used to interpret data.
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 to 70 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- to compare the Radiological Spectrum Of Fatty Liver Correlate With High Resolution Ultrasonography (CT, MRI) Of Fibrosis And Cirrhosis
Key inclusion criteria (2 listed)
- Confirmed diagnosis of fatty liver (steatosis), fibrosis, or cirrhosis.
- Patient consent to undergo imaging and participate in the study.
Key exclusion criteria (5 listed)
- Other Liver Diseases: Exclusion of patients with other significant liver conditions (e.g., viral hepatitis, autoimmune liver diseases) unless specified.
- Pregnant women may be excluded due to imaging concerns.
- Poor quality or incomplete imaging studies.
- Presence of other severe systemic illnesses that could affect liver function or imaging.
- Recent liver surgeries or invasive procedures that might affect imaging results
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| high resolution ultrasonographyto compare high resolution ultrasonography finings with other imaging modalities(CT and MRI) | Radiation | – |
Primary outcome
CT
Time frame: 12 Months
CT used for the image comparision
MRI
Time frame: 12 Months
CT used for the image comparision
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Dec 2024.
- Individual participant dataSharing planned: No
Related trials for Fibrosis
Not yet recruitingPhase 2
Effectiveness of Oxitard Gel Versus Physiotherapeutic and Pharmacological Interventions in Alleviating Oral Submucous Fibrosis: A Phase-II Randomized Control Trial
Oral and Maxillofacial Conditions
RecruitingPhase 2
A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Adult Study Participants With Non-Cystic Fibrosis Bronchiectasis
Non-cystic Fibrosis Bronchiectasis
Recruiting
Optimal Treatment Strategy for Spontaneous Bacterial Peritonitis
Spontaneous Bacterial Peritonitis, Paracentesis
RecruitingPhase 1/2
Phase I/II Study of Pacritinib, A JAK2/IRAK1/CSF1R Inhibitor, in Refractory Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
Graft vs Host Disease
RecruitingPhase 3
A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
NASH With Fibrosis, MASH With Fibrosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Fibrosis and Cirrhosis, run by Superior University at 1 site in Pakistan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 27 Dec 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Pakistan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
CT (time frame: 12 Months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Dec 2024.